2型糖尿病
医学
肥胖
糖尿病
超重
疾病
预期寿命
人口
减肥
内科学
内分泌学
生物信息学
环境卫生
生物
作者
Κλεοπάτρα Αλεξιάδου,Adam Hartley,Tricia M-M. Tan,Ramzi Khamis
标识
DOI:10.1016/j.tcm.2024.03.003
摘要
Obesity and overweight affect almost one third of the European population. Obesity and its associated conditions, including type 2 diabetes, significantly impact healthcare systems, life expectancy and quality of life. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of obesity, with or without diabetes, has provided an effective alternative to metabolic surgery and dietary interventions. We are now beginning to understand their pleiotropic effects beyond weight loss, such as their favourable impact on cardiovascular profiles. The aim of this review is to summarize available preclinical and clinical data on the beneficial effects of GLP-1 receptor agonists on atherosclerosis and cardiovascular disease which has the potential to substantially broaden the scope of their clinical applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI